{"name":"Boston Scientific Corporation","slug":"boston-scientific-corporation","ticker":"","exchange":"","domain":"bostonscientificcorporation.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"cardiovascular","drugs":[{"name":"polidocanol injectable foam, 0.5%","genericName":"polidocanol injectable foam, 0.5%","slug":"polidocanol-injectable-foam-0-5","indication":"Treatment of varicose veins and telangiectasias","status":"phase_3"},{"name":"Anti-coagulation therapy","genericName":"Anti-coagulation therapy","slug":"anti-coagulation-therapy","indication":"Other","status":"phase_3"},{"name":"P2Y12 antagonist","genericName":"P2Y12 antagonist","slug":"p2y12-antagonist","indication":"Other","status":"marketed"},{"name":"Thienopyridine","genericName":"Thienopyridine","slug":"thienopyridine","indication":"Other","status":"phase_3"},{"name":"Varithena®","genericName":"Varithena®","slug":"varithena","indication":"Varicose veins of the great saphenous vein, accessory saphenous vein, and visible varicosities","status":"marketed"},{"name":"polidocanol injectable foam, 1.0%","genericName":"polidocanol injectable foam, 1.0%","slug":"polidocanol-injectable-foam-1-0","indication":"Treatment of varicose veins and spider veins","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Anti-platelet therapy","genericName":"Anti-platelet therapy","slug":"anti-platelet-therapy","indication":"Acute coronary syndrome","status":"phase_3"},{"name":"Anticoagulation with heparin","genericName":"Anticoagulation with heparin","slug":"anticoagulation-with-heparin","indication":"Acute thromboembolism prevention and treatment","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"BGC20-0582","genericName":"BGC20-0582","slug":"bgc20-0582","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]}],"pipeline":[{"name":"Anti-platelet therapy","genericName":"Anti-platelet therapy","slug":"anti-platelet-therapy","phase":"phase_3","mechanism":"Anti-platelet therapy inhibits platelet aggregation to prevent blood clots and reduce thrombotic events.","indications":["Acute coronary syndrome","Stroke prevention","Peripheral arterial disease","Post-percutaneous coronary intervention"],"catalyst":""},{"name":"BGC20-0582","genericName":"BGC20-0582","slug":"bgc20-0582","phase":"phase_2","mechanism":"BGC20-0582 is a drug that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"polidocanol injectable foam, 0.5%","genericName":"polidocanol injectable foam, 0.5%","slug":"polidocanol-injectable-foam-0-5","phase":"phase_3","mechanism":"Polidocanol works by causing endothelial damage and subsequent thrombosis in the targeted vein.","indications":["Treatment of varicose veins and telangiectasias"],"catalyst":""},{"name":"Anti-coagulation therapy","genericName":"Anti-coagulation therapy","slug":"anti-coagulation-therapy","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Anticoagulation with heparin","genericName":"Anticoagulation with heparin","slug":"anticoagulation-with-heparin","phase":"marketed","mechanism":"Heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.","indications":["Acute thromboembolism prevention and treatment","Atrial fibrillation with stroke risk","Deep vein thrombosis prophylaxis and treatment","Pulmonary embolism prophylaxis and treatment","Acute coronary syndrome"],"catalyst":""},{"name":"P2Y12 antagonist","genericName":"P2Y12 antagonist","slug":"p2y12-antagonist","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Thienopyridine","genericName":"Thienopyridine","slug":"thienopyridine","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Varithena®","genericName":"Varithena®","slug":"varithena","phase":"marketed","mechanism":"Varithena is a microfoam formulation of polidocanol that destroys varicose veins by causing endothelial damage and subsequent vein closure.","indications":["Varicose veins of the great saphenous vein, accessory saphenous vein, and visible varicosities"],"catalyst":""},{"name":"polidocanol injectable foam, 1.0%","genericName":"polidocanol injectable foam, 1.0%","slug":"polidocanol-injectable-foam-1-0","phase":"phase_3","mechanism":"Polidocanol works by causing endothelial damage and subsequent thrombosis in the treated vein, leading to fibrosis and closure.","indications":["Treatment of varicose veins and spider veins"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1iQWF2X19lME13QmttTWRSUUJqRlR2dnVfeGRsU2pOVnE5OXlqV0hhSnJaajNmYkhzVFh0T19YU2Z4TE9raHdWVDloc29KSXA5Q3FONXQ4eEtsNVBFZGxxM3lYRFlFV3J3a3NzV25xR3pCU2o1SGJXMTJoQQ?oc=5","date":"2026-04-06","type":"earnings","source":"The Business Journals","summary":"Biotech layoffs pick back up as 14 companies cut 745 jobs in Q1 - The Business Journals","headline":"Biotech layoffs pick back up as 14 companies cut 745 jobs in Q1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNSzdlVkpFeGptTlVsTGJ0TGRUeDdKVC03WjE2TmFZc3dyZGhtb1lkRFpEYTBpbXJUREV4YW4zV2RqUE9EYUdvU3lVYVpIa1p3V2VHcW51eXV6Mnk0dW9RWi1ORmhKVlU1WkRzYW5XUDA0eGpHWG1zLTlrQjZTUk5wTzdDQWdlRHoyU1FyVlJ3VW8xNjVZ?oc=5","date":"2026-02-24","type":"deal","source":"The Business Journals","summary":"Boston Scientific adds Starbucks CFO, Takeda CEO to board amid $14.5B buying spree - The Business Journals","headline":"Boston Scientific adds Starbucks CFO, Takeda CEO to board amid $14.5B buying spree","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPTnFkRkRCN0M0ZV9hZkJiNHE0U3NaR3ZMSTdRY0tnWUd4UGJEaXNwcWVsMy15TlhwbU1wTklMUjd1YXdGSmdKRXQ2cjBPRkZDMG5Ud21NdHN6bThud2FCRUxiSVlEWU1qaVVfR0VhNW1rNmJqM1JoQVoxRlotX09ROW4zWWZfdWd5RFN2TmFHR0JBdVhGXzZfRWx1QVlyQ0M0Wm5ucFViS0JkcVl5TjJVZnJUb0kwb3g4bmNtUUdfYW9kZDUtbFgyVGc1U2NGQQ?oc=5","date":"2026-02-04","type":"pipeline","source":"reuters.com","summary":"Boston Scientific shares fall as key segment's performance spooks investors - reuters.com","headline":"Boston Scientific shares fall as key segment's performance spooks investors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNVVlQMElFcnlldlQ4X3R3Mko5Sy16V3ZJanZUcVpoZzgtLTczbFhpT1B4Z251bkJtM1pvMVY2N0I0bXlObHNDRjJOejQyM3FhQzZ1TVhEby1rSENPSzZCQ0JMRUhWN2MzS2xULXZYUlIxU1BqOXNIZDQ5UkZFbk8tUXkwOUN1V0xRaHMtcEhXMTVXN0lxVnhhRXhFSG4wYnZpZURZQWwzQWhOWU1qbUoxazN2VXpmY2xOSjRjWlF2dEE3X25w?oc=5","date":"2026-01-15","type":"deal","source":"reuters.com","summary":"Boston Scientific beefs up heart device portfolio with $14.5 billion Penumbra deal - reuters.com","headline":"Boston Scientific beefs up heart device portfolio with $14.5 billion Penumbra deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNdjhXTmlZS1diSXVnSlZqblJURFBoZlg2S1F4OVNoSFc0c0dSdjRVYXV1am1XLXA1YXIxLXIxUk9xNFNwd3ZvcTBLbC14Q2pqaWlhSDhUMHNRT00tOURyemUtTjhnY294ZE5PemlFMWZzb0hfd3dqTjE4bE1YXzdGS0lxMA?oc=5","date":"2026-01-15","type":"deal","source":"BioPharma Dive","summary":"Boston Scientific to acquire Penumbra for $14.5B - BioPharma Dive","headline":"Boston Scientific to acquire Penumbra for $14.5B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOWVQ5ZUFMVE03THplXy1yZmVWZVhjZWJHVklFRndMa3dpVXJCNUdCajVfdHRSUHR4NGFzNENzaEptcWdOZGVvR2hZZ1FlUkNuTHJFcEYzbFRUWndfVk5rT3lpOHFtc2RUOVA4cE1aTXVIU1d1NHcwQkU4R0stb3hkeFlZUFl3V1E?oc=5","date":"2025-12-26","type":"pipeline","source":"Yahoo Finance","summary":"A Strong Growth Profile Gives Boston Scientific Corp. (BSX) a Favorable Outlook - Yahoo Finance","headline":"A Strong Growth Profile Gives Boston Scientific Corp. (BSX) a Favorable Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNTUIza0JSQUtsY2NDdV9sT3k4cmRZcGkxLXdJU0M3amZQZUVIMWJpOGhxZVozM1JRSGdXa3UyTFZfUmZzdThrRnM3Vm9lQ3JHd1FhcV9RVEc1Q1VuSUk0a1VTYndpc2lkSkdEbkl0bHQybXFCVEhuUDZhd2EtcmtZRGxnRG1KXzJFeHQwVXFQZHJOc3hyTnFXc0xJYTBlazBralNUSWdmUklmLVVPamVjNUUwd1huOXlk0gG-AUFVX3lxTE1QWll2M3VmVU1rT2dXRDVjdlNUUUc5dVM1anNzNjhhUEZ0bEdNUmh2Q1Vwb2FrVUpGM2sydEdCc0lLOWZ1c1VOWVJGZDFXcWhQUVNEZkJFWVJ4Z1ozMFJLWEg5M1ZPV0U0aktvNlFEaTUzZVRkV05leGtXNVhlVkNSZ3ZzQUdNWXlfSE44OVliaGtOb3ljOFItWWdNY0ZhUmtxdmFHTXhzT3RHZElaYV81MlM3U2VEdEwtcFJsdlE?oc=5","date":"2025-10-20","type":"deal","source":"medicaldialogues.in","summary":"Boston Scientific to acquire Nalu Medical for USD 533 million - medicaldialogues.in","headline":"Boston Scientific to acquire Nalu Medical for USD 533 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNT0Y4d3RLM1ZGQ1YycWFYMEJOS2Ztc3pWam1JY003MXd3S1J1WkNEajdFS2xuVktMdV9xOF9kWjV2RDVXc3UxMnRDTFphaUk1eE52Vl82RmJfcDhjWnZZLXNnTjUzWVlBaTlPTEt2b1JILWZwUTNjbkxSWTNpdGZaYzV1YWdta01CbDBKSjNSclBRV2Z5X1hxVE5RYjdINXU3QjJiazRDeDREdXIwMS1iRTJydkRjNGdvUmhLcTJJWkRwc0dMVUJlcEJ3YUpqdUVoeGc0N1lkYmpLUnRyZVE?oc=5","date":"2025-07-23","type":"earnings","source":"reuters.com","summary":"Boston Scientific lifts annual profit forecast, sees smaller tariff impact - reuters.com","headline":"Boston Scientific lifts annual profit forecast, sees smaller tariff impact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxORGNFcDdOZ2FxcGJMRzZYRTFmbmhDSjloVm5Ebkw3amROdjZWSTU0TWFWQXpreERyQkNrY0lPaDRobkNieWYtSk8yRzU3Y1JrZHZCdGR4Z3NnUnZ3MTlzRnVnZm84a2p2XzZ2Rk44c1NKMVRxWjRWODBCc3VBV2VwODZZWjI5T18tbnBFRw?oc=5","date":"2025-05-18","type":"pipeline","source":"The Business Journals","summary":"Market shift: Boston Scientific emerges as Massachusetts' most valuable public company - The Business Journals","headline":"Market shift: Boston Scientific emerges as Massachusetts' most valuable public company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQc3RQMnFXa3FGUlBjalA1S1ZwYW9YRVFvSy1MWXFXOTdVaHpnUmFIQTFfWFRhUHpnR0xrRkVndFJKeU5tMW1yc0FSVWhkOTdoY2ZIMVlwSm9fYjF3cnVYWm5tTy1GbGZfX1F0NTloenRZcEdlRkFXOXc4Sm1yY0ZORjFKNnRDZ3pCWXhUeWF0RVByMHhzeXJ3dW1GLVlmUzlVQ0hkajZNcHhyc3JvX1ZUVjBpdVVHenBEN0JDd1NBeERSMV9yYUp2Zkw3WDk3S0xWa0k1S3R0RHM3Nl9yU3JOWElDOF9QV0xfaDluZ20wQ2RaQTVZVmlmb1p3cE5XNkh2SkxTMjI3TnV4OUk0R2hwSGFYNDg4V29XVzdxdlhhOA?oc=5","date":"2025-04-23","type":"pipeline","source":"PR Newswire","summary":"Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan - PR Newswire","headline":"Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNZmFRdmR5Wm9nRFVRdEgyVXpHM3U5VmR2cXlhME5oeHJ6NGxLN3dUSlJJNHcyOG1kT2ZvbnNrWFZkMmlNbWpJTFZrX25xaE51ejRITjUxNnRkY2FyYTByR1dhU3g1MDR4LWVQYWRVbmVPUkxjS0tKNHNtckMzQzdWVFdPa2lRdmNWdHZjRkg2UldIQWFrZWJwa1NEWDFKOG1TTmZkUE9Ld1dUQXZ6M2tQbHFFT3pkNXRiZ2hRUF9aY0V1c2hmX2xnLQ?oc=5","date":"2023-09-19","type":"deal","source":"PR Newswire","summary":"Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc. - PR Newswire","headline":"Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNcWh1RmdTTzdsYUppV2tnVWU3NEFvdFRhSUM4RW5fRkFyRXg0RnFrWnhiVjV4WGlYUWhnOTBET3RnOVJpLUpuS0FpM3JEVVBqZVB3MGstdTlZOElUZzNnVVJIRmVWRmQ1M0pfYzg0c3dmaDBrQ0ZlN0x3QWFwR0QyVjVOZUQ3X3FIakpOS3I2MXJLcGZ6SEk0bDhiNDEwME4zS0ozS0lZSE9ZTTVJcDZONGVWN0hONHhPamc?oc=5","date":"2022-06-28","type":"pipeline","source":"Georgia Department of Economic Development","summary":"Boston Scientific Expands Research Capabilities in Georgia with $62.5 Million Investment in Johns Creek - Georgia Department of Economic Development","headline":"Boston Scientific Expands Research Capabilities in Georgia with $62.5 Million Investment in Johns Creek","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_3":5,"phase_2":1,"marketed":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}